Background-Perinatally HIV-infected children (PHIV) may be at risk of undervaccination. Vaccination coverage rates among PHIV and HIV-exposed uninfected children (HEU) in Latin America and the Caribbean were compared.
Results-Of 1156 eligible children, 768 (66.4%) were HEU and 388 (33.6%) were PHIV. HEU children were significantly (p<0.01) more likely to be UTD by 12 and 24 months of age for all vaccines examined. Statistically significant differences persisted when the analyses were limited to children enrolled prior to 12 months of age. Controlling for birth weight, sex, primary caregiver education and any use of tobacco, alcohol or illegal drugs during pregnancy did not contribute significantly to the logistic regression models.
Conclusions-PHIV children were significantly less likely than HEU children to be UTD for their childhood vaccinations at 12 and 24 months of age, even when limited to children enrolled before 12 months of age. Strategies to increase vaccination rates in PHIV are needed.
Keywords
Pediatric HIV infection; vaccination; Latin America Preventive health care, including immunization, is an essential part of comprehensive care that can minimize adverse health outcomes for perinatally HIV-infected children and adolescents. Based on evidence of safety, immunogenicity and, in some cases, efficacy of most childhood vaccines for children with HIV infection, guidelines [1, 2, 3] have been developed for recommended immunization in this population. However, health care staff responsible for immunization delivery may miss opportunities for immunizing HIV-infected children because they are unaware of those recommendations, they are concerned about greater risk with use of vaccines in this population, or other reasons. African [4, 5] and European studies [6, 7, 8] found lower immunization coverage of HIV-infected children compared to uninfected peers, while a North American study found equally low vaccine coverage, for both HIV-infected and the HIV-exposed uninfected populations for some vaccines [9] . In a rural South African population, maternal HIV-positive status was independently associated with lower vaccination rates for four vaccines in children 12-23 month of age (BCG, DTP3, poliomyelitis, and hepatitis B) [10] .
Childhood immunization adequacy can be used as an indicator of children´s primary health care and perhaps highlight areas for improvement. Yet, immunization coverage for HIVinfected children in Latin America and the Caribbean has not been described. Given the importance of vaccination for HIV-infected children and the data from other regions suggesting that they are at higher risk of under-immunization, we evaluated immunization rates, vaccine adverse events (cases associated with polio and BCG vaccines), and the occurrence of vaccine preventable diseases among HIV-exposed uninfected (HEU) and perinatally HIV-infected (PHIV) children in Latin America enrolled in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI).
METHODS
The NISDI Pediatric protocol was a prospective cohort study that followed HIV-infected and perinatally HIV-exposed, uninfected children at multiple clinical sites in Latin America and the Caribbean. A description of an early version of the protocol cohort has been published [11] . When enrollment began in October 2002, HEU infants (up to 12 months of age) and HIV-infected children (≤ 21 years of age) were enrolled from eleven participating sites in Brazil and two sites each in Mexico and Argentina; in 2006 sites in Peru and Jamaica were added. The next version of the protocol, initiated in 2008, continued follow-up of HIVinfected children previously enrolled by six years of age and also enrolled a new group of HIV-infected children less than six years of age, at twelve Brazilian sites and one original site each in Mexico and Peru. The protocol was approved by the ethical review boards of each participating clinical site, by the sponsoring institution (NICHD), the data management and statistical center (Westat), the Peruvian Ministry of Health and the Brazilian National Ethics Committee (CONEP). Informed consent was obtained from parents or guardians of minor participants.
Eligibility for this analysis was limited to HEU and PHIV children born from 2002 through 2007 to control for potential variation in vaccination practice. HEU children were enrolled up to one year of age, while PHIV children were enrolled up to their sixth birthday. All children were born to women with documented HIV infection. Those classified as PHIV had no risk factors other than their mother's HIV infection and were confirmed HIV-infected on the basis of positive HIV tests on two different occasions (virologic tests if under age 18 months, virologic and/or antibody tests if age ≥ 18 months). HEU children had negative HIV virologic testing at ages ≥ one month and ≥ four months or repeatedly negative HIV antibody testing at age ≥ 6 months. Maternal information was collected on all enrolled children, including the reason for taking antiretroviral (ARV) drugs (prophylaxis or treatment), educational level of the primary care provider and substance use during pregnancy. All enrolled children had the following information collected: gestational age, birth weight, and vaccinations received from birth up to the age of enrollment. All children were medically evaluated in a standardized fashion every six months, including laboratory assessments (CD4+ T-lymphocyte [CD4] %, CD4 counts and HIV viral load, if appropriate), and additional vaccinations.
Children were considered up to date (UTD) for a specific vaccine if they had received the recommended number of doses for that vaccine, and the doses followed minimum age and minimum interval guidelines according to World Health Organization recommendations [12] . The definitions for UTD at 12 months by vaccine were: one dose of Bacille CalmetteGuérin vaccine (BCG); three doses of oral polio vaccine (OPV) or two doses of inactivated poliovirus vaccine (IPV); three doses of diphtheria-tetanus-pertussis-containing vaccines (DTP); three doses of Haemophilus influenzae type b vaccine (Hib); and three doses of hepatitis B vaccine (HBV). A child was considered UTD for all vaccines at 12 months if they had received all recommended doses for BCG, OPV/IPV, DTP, Hib, and HBV at the appropriate dosing intervals.
A child was considered to be UTD at 24 months of age for each vaccine as follows: three doses of either OPV or IPV; four doses of DTP; three doses of Hib prior to 12 months of age or at least one dose of Hib given after 12 months of age; three doses of HBV; and one dose of measles-containing vaccine (MV). A child was considered UTD for all vaccines at 24 months of age if they had received all recommended doses for OPV/IPV, DTP, Hib, HBV, and MV at the appropriate intervals.
Vaccine related events (vaccine-associated paralytic polio and adverse BCG vaccine events) and vaccine-preventable diseases (measles, hepatitis B, Hib, pertussis, and polio) were ascertained at the twice yearly study visits.
Statistical Methods
Fisher's exact test was used to evaluate the relationship of demographic characteristics with HIV status. Children were also classified according to vaccine status (UTD, Not UTD, Insufficient follow-up) for each vaccine at 12 and 24 months of age and Fisher's exact test was used to assess its relationship with HIV infection status.
To investigate potential for bias related to younger age at study enrollment of HEU children compared to PHIV children, the analyses were repeated including just the subset of PHIV children enrolled before 12 months of age who were still on study at 24 months of age.
Covariates associated with a child's HIV status (p ≤0.2) were considered candidates for inclusion in multivariable logistic regression modeling. All analyses were conducted using SAS statistical software, version 9.2 (SAS Institute Inc. Cary, NC).
RESULTS
Among the 1926 children enrolled in the NISDI Pediatric protocol, 1161 were born between 2002 and 2007. Five HIV infected children who were horizontally infected were excluded from the analysis. Of the remaining 1156, 768 (66.4%) were HEU and 388 (33.6%) were PHIV. Most participants (843, 72.9%) were enrolled in Brazil. Variables found to be significantly associated with children's HIV status included: country of birth; education of the primary caregiver; reason for maternal ARV use; ever use of tobacco and alcohol and illegal drugs during pregnancy; and child's age at enrollment into NISDI (Table 1) .
HEU children were significantly (p<0.01) more likely to be UTD by 12 months of age for each vaccine; depending on the specific vaccine examined, the probability of being UTD for HEU was approximately two to seven times that of being UTD if PHIV ( Table 2) .
Differences in UTD status between HEU and PHIV were large even for non-live vaccines: Hib (73.3% vs. 52.7%), HBV (85.9% vs. 61.8%) and DTP (79.7% vs. 60.5%). At 24 months of age, HEU children remained significantly (p<0.01) more likely to be UTD for each vaccine, including measles vaccine; the probability of being UTD for HEU was approximately two to three times that of PHIV (Table 2 ). These differences persisted when the analyses were limited to PHIV children enrolled prior to 12 months of age on the NISDI study (Table 3) .
Since most children were from Brazil, the results were driven largely by what occurred among Brazilian study participants. However, sub-analyses of vaccination status by country demonstrated that Peru experienced the same statistically significant differences by HIV status for all vaccines while Argentina showed the same pattern, although the differences reached statistical significance only for hepatitis B (data not shown). There were too few HEU children in Mexico and Jamaica (one and three HEU children, respectively) for any meaningful analyses.
HEU children had a greater probability (odds ratio = 2.4; 95% CI: 1.8, 3.0) of being UTD on all vaccines at 12 months of age than PHIV, with 57.4% of HEU and 36.9% of PHIV having received all recommended doses for BCG, Hib, HBV, DTP and polio by their first birthday ( Table 4 ). The probability of being fully immunized by their second birthday for HEU continued to be two times that of PHIV (95% CI: 1.6-2.6); 48.8% of HEU and 31.8% of PHIV received all the recommended doses for Hib, HBV, DPT, Polio and MV.
A series of logistic regression models were fit to the data for the dependent variables: BCG UTD by 12 months of age, MV UTD at 24 months of age and HBV UTD by 24 months of age, controlling for primary caregiver education, any use of tobacco, alcohol, marijuana or cocaine during pregnancy, and child's birth weight and gender. None of these covariates contributed significantly to the models, and each resulted in only modest changes in the association of HIV status with vaccine UTD status. Site, age at enrollment and maternal reason for ARV were not included in the final modeling as their distributions would otherwise lead to model failure.
No cases of vaccine-associated paralytic polio were reported. However, there were fourteen cases of adverse events related to BCG vaccination, all reported among PHIV children: Among BCG vaccinated PHIV children, 4.8% (95% CI: 2.7-8.1%) experienced a regional event (13 of 273 vaccinated PHIV children) and 0.4% (95% CI: 0-2.2%) had a systemic BCG related event (1 of 273 vaccinated PHIV children).
Both cases of vaccine preventable diseases occurred in PHIV children and were confirmed by culture. : one case of measles in a 20-month-old Brazilian boy who had received one dose of MMR at 13 months of age and one case of Hib pneumonia in a 22-month-old Brazilian boy who had received three doses of Hib prior to one year of age. The child diagnosed with measles in 2006 had been receiving didanosine and zidovudine for five months and had a viral load of 2,000,000 copies/mL; no CD4% was available prior to or at the time of diagnosis. The case of Hib pneumonia occurred in 2009 in a child who had been receiving zidovudine, abacavir and lamivudine for nearly two years, and had a CD4 percent of 24% and viral load of 9,867 copies/mL two months prior to the Hib infection; his CD4% nadir prior to the episode was 15%.
DISCUSSION
The results of this study indicate that PHIV and HEU children in Latin America are at high risk of being incompletely immunized at 12 and 24 months of age. The proportions of children UTD for routine vaccines at 12 months of age ranged from 52.7% for Hib vaccine (PHIV group) to 94.2% for BCG (HEU group). HEU children had significantly better coverage than PHIV children for all vaccines examined. HEU children did experience vaccine coverage under 80% for Hib, DTP, and polio at 12 months of age; however, by 24 months of age vaccine coverage was greater than 80% for all vaccines except the fourth dose of DTT. Although there was an increase in vaccination among PHIV children from 12 to 24 months of age, they had less than 75% coverage for each vaccine. The decline in percentage coverage for DTP from 12 to 24 months of age for both PHIV and HEU children (60.5% to 43.5% and 79.7% to 74.2%, respectively) demonstrates that the recommended fourth dose of DTP was not routinely administered. Measles vaccination was completed for 68.1% of the PHIV and 89.9% of the HEU children by 24 months of age.
Since HEU children were required to enroll prior to age 12 months and PHIV children were enrolled up to age 6 years, we hypothesized that the difference found between these two groups in vaccination status might be attributable to the fact that children enrolled in NISDI prior to their first birthday were being monitored more closely and thus more likely to receive vaccinations than children enrolled after 12 months of age. In addition, children enrolled at this earlier age may have had fuller ascertainment of the vaccine administered in the first year of life. However, even when the analyses were restricted to subjects enrolled in NISDI prior to their first birthday (Table 3) , immunization coverage remained significantly poorer for PHIV children.
As with any observational study, we recognize that the data may be incomplete, such as the reporting of vaccine administrations and the occurrence of minor vaccine related adverse events. However, by restricting our study population to the same birth cohort and using standard definitions to define vaccine doses for determining up to date status, we believe that systematic biases have been minimized and do not account for our findings.
In a study of more than 17,700 Brazilian children born in 2005, 81% had received three doses each of OPV, DTP+Hib, hepatitis B, and one dose each of BCG and MMR vaccines by age 18 months [13] . However, the coverage rate in that study dropped to 68% when only valid doses were counted. When categorizing 3 doses of DTP as complete as in this Brazilian study, the coverage rate in our study for all vaccines in HEU children at 24 months exceeded 80% (data not shown). For individual vaccines, the proportion in the Brazilian study who received the full number of valid doses exceeded 90% for BCG, DTP (3 doses), and polio and was between 80 and 90% for Hib, Hepatitis B and measles. Thus, the coverage rates observed in HEU children in our study were similar to the national vaccine coverage rates for children in Brazil, suggesting good ascertainment of vaccination history in our study. . Good virologic and immunologic response after 12 months of ART among HIV-infected children in resource-limited settings are comparable to those observed among children in developed countries [14] . The success in treatment of HIV infection in children has resulted in more perinatally HIV-infected children growing up with HIV infection, even in low-and middle-resource countries. For this group of children, the vaccination issue has increasing importance, as HIV infection and associated diseases place them at risk for severe vaccinepreventable diseases and their adverse consequences.
Concern about adverse events may contribute to underimmunization of PHIV children. However, it is known that non-live vaccines are not associated with increased risks of complications in HIV-infected children; in contrast, replicating live vaccines could pose risks for these children. Regional and extra regional localized and disseminated diseases have been reported in association with BCG vaccine [15, 16, 17] . The rate of BCG adverse events in this study [4.8% (95% CI: 2.7-8.1%) for regional events and 0.4% (95% CI: 0-2.2%) for distant BCG related events] was consistent with a Brazilian report which found three cases (4.5%) of regional BCG disease and no cases of distant events among 66 HIVinfected children [18] .
The risk of vaccine-associated paralytic poliomyelitis after OPV is theoretically increased in HIV-infected individuals, but only two cases of vaccine-associated paralytic poliomyelitis have ever been reported in HIV-infected children [19, 20] . No cases were observed in our study and though it is possible that a case occurred but was not captured, this clinical syndrome is unlikely to have been missed with prospective study visits every 6 months. As suggested by Moss et al, the benefits of poliovirus vaccination far outweigh the potential risks in HIV-infected children [15] .
Fewer adverse events due to live attenuated vaccines and better response to vaccination, with fewer cases of vaccine preventable diseases, could be attained if children were immunized when their immune systems are not suppressed [21, 22] .
The traditional risk factors for inadequate immunization coverage such as poverty, mothers with low level of education and remote access to the health care service were present in this population; however, this did not explain the difference in vaccination rates between HEU and PHIV children.
Given the recognized impact of these vaccines on reducing childhood morbidity and mortality, the failure in vaccination coverage in the PHIV population is disappointing. Two factors might help explain these results: 1) missed opportunities to complete routine scheduled vaccinations because the children had symptomatic HIV infection or were hospitalized; and 2) misconception and myths about immunization of HIV-infected children among their parents and even physicians´ apprehension related to vaccination.
Although vaccination is an efficacious preventive measure, as well as an economic rational choice [23] , this study highlights poor compliance with routine vaccination of PHIV children in Latin America. Failing to maximize protection in these children against vaccinepreventable diseases not only puts them at risk of substantial morbidity, but also increases the risk of transmission of vaccine-preventable infections to other susceptible members of their communities. New strategies to increase adequate immunization compliance and better protect children from vaccine preventable diseases in this population appear warranted. * P-value < 0.0001 for all comparisons HEU = HIV exposed uninfected; PHIV = perinatally HIV infected; UTD = Up to date; Not UTD = missing one or more doses with at least one study visit after the age of interest; Insufficient FU = missing one or more doses and not followed up to age of interest; BCG = Bacille Calmette-Guérin vaccine; Hib = Hemophilus influenza type b vaccine; DTP = Diphtheria-Tetanus-Pertussis vaccine; HBV = hepatitis B vaccine; MV = measles-containing vaccine.
NA 1
-not applicable as BCG was not re-examined at 24 months of age;
NA 2
-not available as measles vaccination first recommended at 12 months of age UTD at 12 months = 1 dose BCG; 3 doses Hib; 3 doses HBV; 3 doses DTP; 3 doses oral polio vaccine (OPV) or 2 doses inactivated poliovirus vaccine (IPV); 1 dose MV. UTD at 24 months = either 3 doses Hib prior to 12 months or at least one dose Hib given after 12 months; 3 doses HBV; 4 doses DTP; 3 doses either OPV or IPV: 1 dose MV.
Table 4
Vaccination status at 12 and 24 months of age among children born from 2002-2007 that were enrolled in NISDI, by HIV status 1.0 HEU = HIV exposed uninfected; PHIV = perinatally HIV infected; UTD = Up to date; Not UTD = missing one or more doses with at least one study visit after the age of interest.
All vaccines UTD at 12 months includes: BCG, Hib, HBV, DTP and Polio.
All vaccines UTD at 24 months includes: Hib, HBV, DTP, Polio, and MV. None UTD: None of the targeted vaccines was UTD at the specified age.
